Emcure Pharma

Why is Emcure Pharmaceuticals Ltd falling/rising?

As of 22-Jun, Emcure Pharmaceuticals Ltd's stock price is rising, currently at 1,792.70, with a year-to-date increase of 31.41% and a 36.84% rise over the past year, significantly outperforming the Sensex. Despite a decline in investor participation, the stock's strong fundamentals and positive trends indicate healthy long-term growth prospects.

As of 22-Jun, Emcure Pharmaceuticals Ltd's stock price is rising, currently at 1,792.70, reflecting an increase of 18.65 (1.05%). The stock has shown a strong performance over various periods, with a year-to-date increase of 31.41%, significantly outperforming the Sensex, which has declined by 9.54% during the same timeframe. Over the past year, the stock has risen by 36.84%, again surpassing the market's performance.<BR><BR>Today, the stock is trading close to its 52-week high, just 2.18% away from Rs 1,830.35, and has experienced consecutive gains over the last three days, accumulating a total return of 3.94%. Additionally, Emcure Pharmaceuticals is trading above its moving averages across multiple time frames, indicating a positive trend.<BR><BR>Despite a notable decline in investor participation, with delivery volume dropping by 71.92% against the 5-day average, the stock remains liquid enough for trading. The company's strong fundamentals, including a high return on capital employed (ROCE) of 21.82% and a low debt-to-EBITDA ratio of 0.84 times, contribute to its healthy long-term growth prospects, with net sales and operating profit growing at annual rates of 15.40% and 16.32%, respectively. These factors collectively support the stock's rising price.

Which are the latest news on Emcure Pharma?

What does Emcure Pharma do?

Emcure Pharmaceuticals Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹2,470 Cr and a net profit of ₹243 Cr for the quarter ending March 2026. It has a market cap of ₹34,150 Cr and key metrics include a P/E of 35.00 and a return on equity of 19.15%.

Overview:<BR>Emcure Pharmaceuticals Ltd is a small-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Emcure Pharmaceuticals Limited was originally incorporated as 'Emcure Pharmaceuticals Private Limited' in 1981. It was later converted into a Public Company and renamed 'Emcure Pharmaceuticals Limited' in 2001. The most recent quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 2,470 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 243 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 34,150 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.17% <BR>Debt-Equity: 0.28 <BR>Return on Equity: 19.15% <BR>Price to Book: 6.68 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Emcure Pharma?

As of 10th June, Emcure Pharmaceuticals Ltd has a market capitalization of 34,150.00 Cr, with net sales of 9,203.54 Cr and a net profit of 924.35 Cr reported in the latest four quarters. The company has shareholder's funds of 4,446.19 Cr and total assets of 8,121.73 Cr for the annual period ending March 2025.

As of 10th June, Emcure Pharmaceuticals Ltd has a market capitalization of 34,150.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Emcure Pharmaceuticals reported net sales of 9,203.54 Cr and a net profit of 924.35 Cr.<BR><BR>For the latest annual period ending March 2025, the company had shareholder's funds amounting to 4,446.19 Cr and total assets of 8,121.73 Cr.

Who are the peers of the Emcure Pharma?

Emcure Pharma's peers include Ipca Labs, Gland Pharma, Ajanta Pharma, Glaxosmi Pharma, J B Chemicals, Wockhardt, Acutaas Chemical, Sai Life, and Neuland Labs. Emcure has good management risk and growth, with a 1-year return of 25.96%, outperforming Glaxosmi Pharma but underperforming Acutaas Chemical.

Peers: The peers of Emcure Pharma are Ipca Labs, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, J B Chemicals &, Wockhardt, Acutaas Chemical, Sai Life, and Neuland Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma and Glaxosmi. Pharma, while Good management risk is found at Ipca Labs, J B Chemicals &, Emcure Pharma, Acutaas Chemical, and Neuland Labs. Average management risk is noted at Wockhardt and Sai Life. Growth is Excellent at Acutaas Chemical and Sai Life, while Good growth is seen at Emcure Pharma and Neuland Labs. The rest of the peers, including Ipca Labs, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, J B Chemicals &, and Wockhardt, exhibit Below Average growth. Capital Structure is Excellent for Ipca Labs, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, J B Chemicals &, Acutaas Chemical, Sai Life, and Neuland Labs, while Good capital structure is found at Emcure Pharma. Wockhardt has a Below Average capital structure.<BR><BR>Return Snapshot: Acutaas Chemical has the highest 1-year return at 186.73%, while Glaxosmi. Pharma has the lowest at -36.01%. Emcure Pharma's 1-year return of 25.96% is significantly higher than Glaxosmi. Pharma's return but lower than Acutaas Chemical's. Additionally, Wockhardt and Piramal Pharma have negative six-month returns.

Are Emcure Pharmaceuticals Ltd latest results good or bad?

Emcure Pharmaceuticals Ltd's latest results show strong revenue growth with a net profit increase of 28.81% and net sales up by 16.70%. However, declining operating margins and rising interest expenses indicate potential operational challenges that investors should consider.

Emcure Pharmaceuticals Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹243.40 crores for Q4 FY26, reflecting a strong year-on-year growth of 28.81%. Additionally, net sales reached ₹2,469.70 crores, marking a robust 16.70% increase compared to the same quarter last year. This indicates solid revenue growth and the company's ability to capture market share.<BR><BR>However, there are concerns regarding margin pressures. The operating margin (excluding other income) decreased to 19.42%, down from 20.85% in the previous quarter, indicating challenges in maintaining profitability amidst rising costs. Furthermore, interest expenses surged to ₹46.40 crores, representing a significant increase, which could impact future profitability.<BR><BR>Overall, while the revenue and profit growth are commendable, the decline in operating margins and rising interest costs suggest that the company is facing operational challenges. Investors may need to weigh these factors carefully when assessing the company's performance.

Should I buy, sell or hold Emcure Pharmaceuticals Ltd?

When is the next results date for Emcure Pharmaceuticals Ltd?

The next results date for Emcure Pharmaceuticals Ltd is 05 May 2026.

The next results date for Emcure Pharmaceuticals Ltd is scheduled for 05 May 2026.

How has been the historical performance of Emcure Pharma?

Emcure Pharma has demonstrated strong historical performance, with net sales increasing from 5,985.81 Cr in March 2023 to 7,896.00 Cr in March 2025, alongside rising profits and improved earnings per share. Despite a decline in cash flow from operating activities, the overall financial metrics indicate robust growth in sales and profitability.

Answer:<BR>Emcure Pharma has shown a positive trend in its historical performance, with significant growth in net sales and profits over the past three years.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Emcure Pharma reported net sales of 7,896.00 Cr, an increase from 6,658.25 Cr in March 2024 and 5,985.81 Cr in March 2023. The total operating income mirrored this growth, reaching 7,896.00 Cr in March 2025. The company's total expenditure also rose to 6,421.62 Cr, up from 5,428.53 Cr in the previous year. Operating profit (PBDIT) increased to 1,541.64 Cr in March 2025, compared to 1,286.71 Cr in March 2024. Profit before tax reached 971.35 Cr, up from 727.23 Cr, and profit after tax was 707.47 Cr, an increase from 527.58 Cr in the prior year. The consolidated net profit for March 2025 was reported at 681.33 Cr, up from 498.18 Cr in March 2024. The company's earnings per share also improved, reaching 35.96 in March 2025 from 27.5 in March 2024. On the balance sheet, total assets increased to 8,121.73 Cr in March 2025, while total liabilities rose to 8,121.73 Cr as well. The cash flow from operating activities was 851.00 Cr, down from 1,097.00 Cr in the previous year, resulting in a net cash outflow of 58.00 Cr for March 2025. Overall, Emcure Pharma's financial metrics indicate a robust growth trajectory in sales and profitability, despite some fluctuations in cash flow.

Is Emcure Pharma technically bullish or bearish?

As of November 4, 2025, Emcure Pharma shows a mildly bullish trend overall, despite some bearish signals from weekly indicators like MACD and Bollinger Bands.

As of 4 November 2025, the technical trend for Emcure Pharma has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and Bollinger Bands are showing mildly bearish signals. The RSI has no signal on both the weekly and monthly time frames, suggesting a lack of momentum. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators on the weekly charts.

Is Emcure Pharma overvalued or undervalued?

As of September 23, 2025, Emcure Pharma is considered overvalued with a PE Ratio of 33.30, an EV to EBITDA of 16.59, and a Price to Book Value of 5.65, underperforming the Sensex with a year-to-date return of -8.07%.

As of 23 September 2025, Emcure Pharma's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE Ratio of 33.30, an EV to EBITDA of 16.59, and a Price to Book Value of 5.65. <BR><BR>In comparison to its peers, Emcure Pharma's PE Ratio is slightly lower than Sun Pharma's 34.11 but significantly higher than Cipla's 22.93, indicating a premium valuation relative to some competitors. Additionally, Emcure's PEG Ratio stands at 0.00, which is notably lower than the industry average, suggesting potential growth concerns. Recent stock performance has underperformed against the Sensex, with a year-to-date return of -8.07% compared to the Sensex's gain of 5.07%, reinforcing the notion that the stock may be overvalued.

Who are the top shareholders of the Emcure Pharma?

The top shareholders of Emcure Pharma include Satish R Mehta with 39.79%, Bc Investments IV Limited at 8.68%, and individual investors with 5.51%. Mutual funds hold 2.73%, while foreign institutional investors own 3.07%, with pledged promoter holdings at 0.0406%.

The top shareholders of Emcure Pharma include the promoters, with Satish R Mehta holding the highest stake at 39.79%. Other significant shareholders are Bc Investments IV Limited, which holds 8.68%, and individual investors who collectively own 5.51%. Additionally, mutual funds have a presence with 21 schemes holding 2.73%, while foreign institutional investors (FIIs) hold 3.07% through 48 different entities. The pledged promoter holdings are relatively low at 0.0406%.

Has Emcure Pharma declared dividend?

No Dividend History Available